Figure 8

Schematic diagram of the filtering method used to narrow down the drug candidates. 13 drugs were identified as the intersection of the drug candidates by transcriptomic, proteomic and interactomic analyses (Fig. 7). 11 proteins were identified as the intersection between signature proteins of proteomic analysis and human proteins in human-viral PPI (Fig. 4). 115 pathways were identified as the intersection between significant pathways determined by GSEA of transcriptomic analysis and that of proteomic analysis (Fig. 5). Firstly, nine proteins were selected as the intersection between proteins interacted with 13 drugs and 11 signature proteins. These nine proteins were interacted with eight drugs out of 13 drugs. Secondly, seven proteins were selected as the intersection between proteins participating in 115 pathways and 11 signature proteins. These seven proteins were mapped in 43 pathways out of 115 pathways. Finally, five proteins were selected as the intersection between nine proteins interacted with 13 drugs and seven proteins participating in 43 pathways. These five proteins were interacted with eight drugs, and were participating in 33 pathways out of 43 pathways. Then, eight drugs were identified as candidates for use in future drug repositioning.